{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}],"title":"ADA Positive: Overall Incidence"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}],"title":"NAb Positive: Overall Incidence"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"description":"A participant was ADA (or NAb) positive if: (1) baseline titer was missing or negative and participants had \\>1 post-treatment positive titer (treatment-induced), or (2) positive titer at baseline and had a \\> \\[4-fold dilution increase\\] in titer from baseline in \\>1 post-treatment sample (treatment-boosted).","groups":[{"description":"Participants with advanced relapsed or refractory lymphomas received TTI-621 0.05 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"OG000","title":"Part 1: Ontorpacept (PF-07901800/TTI-621) 0.05 mg/kg"},{"description":"Participants with advanced relapsed or refractory lymphomas received TTI-621 0.1 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"OG001","title":"Part 1: Ontorpacept (PF-07901800/TTI-621) 0.1 mg/kg"},{"description":"Participants with advanced relapsed or refractory lymphomas received TTI-621 0.2 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"OG002","title":"Part 1: Ontorpacept (PF-07901800/TTI-621) 0.2 mg/kg"},{"description":"Participants with advanced relapsed or refractory lymphomas received TTI-621 0.3 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"OG003","title":"Part 1: Ontorpacept (PF-07901800/TTI-621) 0.3 mg/kg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Immunogenicity analysis population included all treated participants with at least one ADA sample (pre-dose or post-treatment) analyzed. Here, \"Number of Participants Analyzed\" signifies number of participants who were ADA or NAb evaluable.","reportingStatus":"POSTED","timeFrame":"Part 1: From pre-infusion on day 1 up to end of study treatment (maximum treatment exposure for Part 1 was 414 days)","title":"Part 1: Number of Participants With Positive Anti-Drug Antibody (ADA) and Neutralizing Antibodies (NAb)","type":"SECONDARY","unitOfMeasure":"Participants"}